Abstract
Lantheus Holdings, Inc. will report first-quarter 2026 results on May 5, 2026 Pre-Market; this preview distills consensus forecasts, last quarter’s scorecard, segment dynamics, and the key drivers investors should monitor.
Market Forecast
Consensus for the current quarter points to revenue of 353.94 million US dollars, a year-over-year decrease of 6.62%, with adjusted EPS expected around 1.24, down 25.48% year over year; EBIT is modeled at 112.67 million US dollars, down 27.21% year over year. Management has not provided explicit numeric targets for gross margin or net margin for this quarter in the prior update, and current sell-side models imply some margin compression versus the prior-year period on mix and pricing.
The company’s core revenue engine remains its precision diagnostics franchise centered on PYLARIFY, which analysts expect to remain resilient in utilization as the business navigates near-term pricing headwinds and prepares to support adoption of the new TruVu formulation later in the year. Within the portfolio, PYLARIFY delivered 989.12 million US dollars in the most recently reported period and, as the largest franchise, is positioned to drive medium-term growth; the company’s total revenue grew 4.01% year over year in the latest quarter.
Last Quarter Review
In the most recent quarter, Lantheus reported revenue of 406.79 million US dollars with a gross profit margin of 59.21%, GAAP net profit attributable to the parent company of 54.09 million US dollars for a net profit margin of 13.30%, and adjusted EPS of 1.67, up 5.03% year over year.
One notable highlight was profitability momentum: GAAP net profit rose 94.76% quarter over quarter, reflecting operating leverage and a favorable comparison. In terms of business mix, PYLARIFY contributed 989.12 million US dollars and DEFINITY contributed 330.25 million US dollars within the company’s reported segment revenue set, anchoring performance as total company revenue increased 4.01% year over year.
Current Quarter Outlook
PYLARIFY and precision diagnostics franchise
Lantheus’s precision diagnostics franchise centered on PYLARIFY is expected to continue providing the bulk of cash generation, even as price/discount dynamics weigh on year-on-year comparisons for the quarter. The approval of PYLARIFY TruVu on March 7, 2026 is strategically important, though its commercial lift is expected to be more visible in the back half of the year given the indicated launch timing in the fourth quarter. For the quarter being reported, consensus focuses on stable underlying procedure volumes and site utilization, with pricing a larger swing factor than volume based on recent channel commentary from covering analysts.
Mix within the precision diagnostics portfolio matters for margins. PYLARIFY’s scale can support manufacturing and distribution efficiencies, but any incremental discounting or payer dynamics will show up through gross margin line pressure versus the prior-year period. The company’s operating expense cadence is expected to reflect continued investment behind commercial readiness for TruVu and other near-term catalysts, though cost control in non-core spend is viewed as supportive of earnings in a softer revenue quarter. As a result, models embed lower adjusted EPS year over year despite the franchise’s healthy usage trends, with the delta largely explained by pricing and timing of investments rather than a step down in demand.
Regulatory and label dynamics have also been topical for investors measuring sustainability. The TruVu formulation gives the company additional product flexibility and may improve logistics for sites, which can enhance consistency of supply and scheduling as utilization scales. While the financial impact in the current quarter is likely modest, the operational read-through is supportive of volume durability and could mitigate periodic distribution bottlenecks observed in high-throughput imaging centers. That view is consistent with recent analyst notes that emphasize resilient PYLARIFY performance and steady cash generation despite near-term pricing headwinds.
Pipeline catalysts and the next growth wave
Beyond the base business, the company’s regulatory progress in the first months of 2026 adds a set of tangible near- and mid-term catalysts. On March 2, 2026, the company received tentative approval for PNT2003 (Lutetium Lu 177 Dotatate), with full approval tied to the expiration of a 30‑month Hatch‑Waxman litigation stay expected to run through June. Although PNT2003 is not a revenue driver for the quarter being reported, the tentative approval significantly de-risks the regulatory path and sets a clear line of sight to commercial timing, which has been a key topic in institutional discussions.
On March 17, 2026, the company disclosed a three‑month extension of the PDUFA date for LNTH‑2501 (Ga 68 edotreotide), a PET diagnostic imaging kit for SSTR+ neuroendocrine tumors. This extension shifts a potential decision into the second half of 2026, tempering near-term expectations but preserving the probability of adding another diagnostic asset with synergy potential across the commercial footprint. Together with TruVu, these regulatory events outline a staggered catalyst calendar that investors can use to frame revenue and margin inflections beyond the present quarter.
Strategically, the pipeline mix complements the existing precision diagnostics footprint and, if executed, can expand the company’s addressable opportunities within its chosen indications while leveraging the same commercial infrastructure. For the current quarter, however, the financial impact is more about expense phasing for launch readiness and ensuring supply readiness than about top-line contribution. That is why consensus currently embeds year-over-year declines in revenue and earnings, with a constructive bias to the out-year setup as approvals and launches accumulate. The majority of covering analysts treat this quarter as a bridge that sets up a stronger second half, particularly as TruVu enters the market and PNT2003 transitions from tentative to full approval following the end of the litigation stay.
What will move the stock this quarter
Guidance granularity will likely be the primary stock driver around the print. Investors will look for any update to full-year revenue and adjusted EPS ranges, commentary on the pricing environment for PYLARIFY, and how management is planning for TruVu ramp timing. Clarity on the magnitude and duration of pricing headwinds can reshape the slope of quarterly estimates and either validate or challenge the current consensus that anticipates a year-over-year compression in margins this quarter.
Regulatory timelines will also influence sentiment. Any commentary confirming that the PNT2003 litigation stay is on track to expire in June, and that operational and commercial readiness is aligned with potential launch windows, can support the multi-quarter growth narrative embedded in the higher end of analyst price targets. Similarly, updated expectations on the LNTH‑2501 review following the three‑month extension can calibrate investor models for potential contribution in late 2026 and beyond.
Finally, operating leverage and cash generation remain key to the model. Last quarter’s GAAP net profit improved sharply quarter over quarter, and the company outperformed EPS expectations, reinforcing confidence in cost discipline. For this quarter, the balance between sustaining growth investments and protecting margins will be scrutinized, especially as consensus already bakes in a 6.62% revenue decline and a 25.48% adjusted EPS decline year over year. Evidence of sustained free cash flow conversion and disciplined capital allocation, including whether the company prioritizes pipeline acceleration or other initiatives, may offset headline softness in revenue comparisons and help frame the trajectory of earnings reacceleration into the back half of the year.
Analyst Opinions
The balance of opinions within the January 1, 2026 to April 28, 2026 window is bullish. Recent updates include a maintained Buy rating with a 105.00 US dollars price target from Jefferies, a maintained Buy with an 85.00 US dollars price target from TD Cowen, and a lifted price target to 98.00 US dollars with a Buy rating from Truist. Across these updates, the ratio of bullish to bearish views is 100% bullish among the institutions cited in this period, and broader surveys of covering analysts continue to characterize the stock with a Buy-average rating and higher mean price targets versus earlier in the year.
The majority view emphasizes three pillars. First, analysts see the PYLARIFY franchise as resilient, supported by stable utilization trends and the strategic addition of the TruVu formulation, which is expected to enhance operational reliability and adoption as it moves toward commercial launch in the fourth quarter. Second, cash generation and recent execution against quarterly expectations are viewed as supportive of valuation, providing flexibility to fund pipeline and launch activities while navigating near-term price/discount dynamics. Third, the pipeline catalysts recorded in the first quarter of 2026—tentative approval for PNT2003 and the PDUFA timeline extension for LNTH‑2501—reshape the out-year revenue scenario with more visibility, which underpins raised or reiterated Buy targets.
Jefferies’ recent reiteration highlights that the forecast pullback in earnings this quarter is well flagged and that the bigger swing factor for the stock is how management frames second-half momentum as TruVu transitions to market and PNT2003 approaches the end of its stay. TD Cowen’s latest note underscores resilient PYLARIFY performance and cash generation despite near-term pricing headwinds, which aligns with the consensus modeling of a softer first quarter followed by improving fundamentals. Truist’s target increase reflects a view that the company’s execution and growing visibility on late-2026 contributions provide a favorable setup relative to current estimates.
In aggregate, the majority of analysts expect a muted headline quarter on year-over-year comparisons, yet they emphasize the improving trajectory into the second half and beyond as catalysts convert. They note that explicit updates on pricing, margin cadence, and launch timing could drive estimate revisions, and that clarity on the June litigation stay for PNT2003 is a meaningful input for scenarios on the next commercial wave. Against this backdrop, the bullish camp continues to frame the shares as levered to operational delivery on the core diagnostics business, confirmation of pricing stability, and milestone execution on the newly approved or pending assets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments